ClinicalTrials.gg
WithdrawnNCT01890200Updated Apr 28, 2017

The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)

A Phase 3 interventional study of Peginterferon alfa-2a and Ribavirin in Chronic Hepatitis C, sponsored by TCM Biotech International Corp.. Withdrawn at 2 sites in 2 countries. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-04-28.

Sponsored by TCM Biotech International Corp. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Hepatitis C, Chronic with a site in China — 2 open to participants now, 2 under way, none of them phase 3. Hepatitis C, Chronic · China.

Enrollment
34th of 34
0 · median 120
Started
2015
with 8 others
Phase 3
13 of 44
none open now
Registered
10th of 44
by date

Among the 44 studies in Hepatitis C, Chronic with a site in China, this one is the 34th largest by enrollment of the 34 interventional ones that give a count, is one of 9 that started in 2015, is one of 13 in phase 3, and was the 10th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

2 of the 44 studies in Hepatitis C, Chronic with a site in China are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 20 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Hepatitis C, Chronic with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double blind, multi-center, placebo controlled, three parallel arms, Phase IIb/III clinical study to evaluate the effects of adding a TCM-700C with a low or high dose onto the combination treatment (PegIFN plus RBV) for subjects with naive genotype 1 HCV infection.

This will be demonstrated by a higher sustained virologic response rate, defined as the absence of detectable HCV RNA 24 weeks after the termination of combination treatment, compared with the placebo add-on.

Read the detailed description

Eligible subjects with written informed consent will be stratified according to their baseline HCV RNA (≤800,000 IU/mL versus>800,000 IU/mL), stage of liver fibrosis (METAVIR system fibrosis score of 0 1 versus 2 3).

During the 48 week Treatment Period and 24 week Follow up Period, subjects will be assessed at regular intervals for efficacy and safety at Weeks 2, 4, 8, 12, 16 and then every 8 weeks thereafter until study completion. If possible, subjects who prematurely discontinue the study during the Treatment Period will have samples taken for hematology, biochemistry and urinalysis in the same week of discontinuation as well as 24 weeks after discontinuation.

03

Conditions studied

  • Chronic Hepatitis C

Browse trials for

Keywords

  • add-on treatment
  • botanical drug
  • HCV genotype 1
  • TCM-700C
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects who are 20 to 65 years old (inclusive), of either gender and in any ethnical group in Asia.
  • Chronic , positive with both antibody to hepatitis C virus (anti HCV) and HCV RNA assays.
  • Confirmed HCV genotype 1.
  • Subjects who are indicated to have combination treatment of PegIFNα 2a and RBV at the discretion of the investigator.
  • All fertile males and females receiving RBV must be using two forms of effective during treatment with study drugs and 6 months post treatment completion.
  • Subjects must voluntarily give written indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
  • Subjects must be able to comply with the assessments during the study.
  • Subjects must be able to understand study QoL questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any IFN α or any medicines that contain Cordyceps.
  • Prior treatment of with any other antiviral or immune modulators.
  • therapy administered within 4 weeks, or within a time interval less than at least 5 half lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study.
  • Subjects diagnosed with hepatocellular carcinoma (HCC) by or α fetoprotein (AFP) serology and radiology (helical computed tomography [CT] and/or magnetic resonance imaging [MRI]) within 5 years of signing the form.
  • Evidence of hepatic decompensation (history or current evidence of ascites, bleeding varices or hepatic encephalopathy).
  • History or evidence of other liver diseases other than chronic HCV infection.
  • Subjects with known allergy or to any ingredient of the study drug or placebo.
  • Pregnant, planning on becoming pregnant, or breastfeeding female subject or male subject whose partner is pregnant or planning on becoming pregnant.
  • Subject with any of the following laboratory abnormalities:

    1. count \<90,000/mm3;
    2. \<1500 cells/mm3;
    3. \<12 g/dL for women and \<13 g/dL for men;
    4. Creatinine >1.5 mg/dL;
    5. (ALT) and/or aspartate aminotransferase (AST) >10 x (ULN);
    6. Total serum >1.5 x ULN;
    7. Subjects without cirrhosis and AFP >50 ng/mL must have an ultrasound between the screening and baseline visit with no findings suspicious for HCC.
  • Medical conditions which are for PegIFNα 2a or RBV therapy:

    1. Psychiatric disorders;
    2. Organ transplant (other than cornea or hair transplant or skin graft);
    3. Severe concurrent medical disease such as severe hypertension, significant coronary heart disease, poorly controlled diabetes mellitus ( A1c [HbA1c] >8.5%), not adequately controlled thyroid dysfunction, , severe infections (bacterial, viral, fungal, including acute tuberculosis), or hemoglobinopathies (thalassemia major or sickle cell anemia);
    4. hepatitis or other autoimmune conditions known to be exacerbated by PegIFNα 2a and RBV.
  • History of a severe seizure disorder or current anticonvulsant use.
  • Evidence of severe retinopathy (e.g., cytomegalovirus retinitis, macular degeneration) or ophthalmological disorder (e.g., due to diabetes mellitus or hypertension).
  • Other cases judged by the investigator to be ineligible for participation in the study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    TCM-700C (low dose)

    an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C

    Drug: Peginterferon alfa-2a · Drug: Ribavirin · Drug: TCM-700C

  • Experimental
    TCM-700C (high dose)

    an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C

    Drug: Peginterferon alfa-2a · Drug: Ribavirin · Drug: TCM-700C

  • Placebo comparator
    Placebo

    placebo add on(t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C

    Drug: Peginterferon alfa-2a · Drug: Ribavirin · Drug: Placebo

Interventions

  • conventional treatment of Hepatitis C

    Also known as: Pegasys

  • conventional treatment of Hepatitis C

    Also known as: Rebetol

  • DrugTCM-700C

    An add-on drug to conventional treatment of Hepatitis C

  • DrugPlacebo

    Placebo, without acting ingredient.

    Also known as: Placebo, without acting ingredient.

06

What researchers measure

Primary outcomes

  1. sustained virologic response (SVR) rate

    undetectable HCV RNA 24 weeks after the EOT.

    Time frame: 24 weeks after the end of treatment (EOT, 48 weeks)

Secondary outcomes

  1. Virologic response (VR)

    undetectable HCV RNA at the EOT.

    Time frame: at the EOT (48 weeks)

  2. relapse rate

    undetectable HCV RNA at the EOT followed by a positive HCV RNA level within 24 weeks after the EOT

    Time frame: 24 weeks after the EOT

07

Study locations

2 sites
  • Peking University People's Hospit
    Beijing, Beijing 100044, China
  • Chang Gung Memorial Hospital
    Taoyuan, 333, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of Mar 2018 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2013
First posted
Jul 1, 2013
Start
Jun 2015
Primary completionEst.
Mar 2018
CompletionEst.
Jun 2018
Last update
Apr 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01890200
Lead sponsor
TCM Biotech International Corp.
Responsible party
Sponsor
First posted
Jul 1, 2013
Start date
Jun 2015
Primary completion
Mar 2018 (estimated)
Completion
Jun 2018 (estimated)
Last update
Apr 28, 2017

Study contacts

I-Shyan Sheen, MD
principal investigator · Chang Gung Memorial Hospital
Lai Wei, MD
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion